SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) is one of 846 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare SAB Biotherapeutics to similar businesses based on the strength of its earnings, valuation, profitability, risk, analyst recommendations, institutional ownership and dividends.
Risk and Volatility
SAB Biotherapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics’ competitors have a beta of 1.11, indicating that their average stock price is 11% more volatile than the S&P 500.
Institutional & Insider Ownership
7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 7.4% of SAB Biotherapeutics shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares SAB Biotherapeutics and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SAB Biotherapeutics | N/A | -6.74% | -6.06% |
| SAB Biotherapeutics Competitors | -9,054.47% | -198.89% | -30.64% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for SAB Biotherapeutics and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SAB Biotherapeutics | 1 | 1 | 9 | 0 | 2.73 |
| SAB Biotherapeutics Competitors | 9775 | 15022 | 45310 | 1577 | 2.54 |
SAB Biotherapeutics currently has a consensus target price of $12.00, indicating a potential upside of 258.96%. As a group, “Biotechnology” companies have a potential upside of 94.92%. Given SAB Biotherapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe SAB Biotherapeutics is more favorable than its competitors.
Earnings & Valuation
This table compares SAB Biotherapeutics and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| SAB Biotherapeutics | $1.32 million | $13.27 million | -2.57 |
| SAB Biotherapeutics Competitors | $718.48 million | $12.73 million | -9.91 |
SAB Biotherapeutics’ competitors have higher revenue, but lower earnings than SAB Biotherapeutics. SAB Biotherapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Summary
SAB Biotherapeutics beats its competitors on 8 of the 13 factors compared.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
